Trial Profile
A phase III trial of the Herceptin biosimilar ALT-02
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 28 Apr 2017
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 28 Apr 2017 New trial record
- 20 Apr 2017 This trial is expected to begin in 2017, according to an Alteogen media release.